QUEBEC CITY, June 13 /CNW Telbec/ - DiagnoCure Inc. (TSX: CUR), a life
sciences company commercializing high-value cancer diagnostic tests and
delivering lab services, announced a net loss of $3,372,374 or $0.08 per share
for the second quarter ending April 30, 2008. These results are substantially
in line with Management expectations. They reflect the significant progress
towards the commercialization of DiagnoCure's new Previstage(TM) GCC
Colorectal Cancer Staging Test, and royalties of the sales of the PCA3 test
progressing over last year second quarter. At the end of the quarter, cash,
short-term investments and long-term investments stood at $26,691,514.
